{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:33:35Z","timestamp":1793453615518,"version":"4.5.0"},"reference-count":217,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017501","name":"Science-Health Joint Medical Scientific Research Project of Chongqing","doi-asserted-by":"publisher","award":["2023DBXM001"],"award-info":[{"award-number":["2023DBXM001"]}],"id":[{"id":"10.13039\/100017501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82674905"],"award-info":[{"award-number":["82674905"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304368"],"award-info":[{"award-number":["82304368"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.mtbio.2026.103715","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:47:19Z","timestamp":1790750839000},"page":"103715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A bottleneck-first evaluation of antigen delivery platforms for therapeutic cancer vaccines"],"prefix":"10.1016","volume":"41","author":[{"given":"Shuai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shentao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9839-0526","authenticated-orcid":false,"given":"Dingkang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mtbio.2026.103715_bib1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat. Med."},{"issue":"10427","key":"10.1016\/j.mtbio.2026.103715_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.mtbio.2026.103715_bib3","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103715_bib4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s43018-025-00966-7","article-title":"Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial","volume":"6","author":"Saxena","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.mtbio.2026.103715_bib6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","volume":"22","author":"Peng","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.mtbio.2026.103715_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"6230","key":"10.1016\/j.mtbio.2026.103715_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103715_bib10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"7662","key":"10.1016\/j.mtbio.2026.103715_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.mtbio.2026.103715_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103715_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.mtbio.2026.103715_bib15","first-page":"924","article-title":"Biomaterials nanoplatform-based tumor vaccines for immunotherapy","volume":"51","author":"Li","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.mtbio.2026.103715_bib16","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/s41565-025-02021-z","article-title":"Progress in cancer vaccines enabled by nanotechnology","volume":"20","author":"Kim","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103715_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41541-021-00330-7","article-title":"Protein-based antigen presentation platforms for nanoparticle vaccines","volume":"6","author":"Nguyen","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.mtbio.2026.103715_bib18","first-page":"498","article-title":"Advances in delivery technologies-powered cancer vaccines","volume":"61","author":"Huang","year":"2026","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.mtbio.2026.103715_bib19","article-title":"Molecular engineering of the nano-bio interface for programmable and precision protein delivery","author":"Ma","year":"2026","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103715_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123615","article-title":"Cancer vaccines: discovery, development, and challenges for clinical translation","volume":"325","author":"Zhang","year":"2026","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.mtbio.2026.103715_bib21","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3390\/vaccines13121222","article-title":"Engineering anti-tumor immunity: an immunological framework for mRNA cancer vaccines","volume":"13","author":"Roy","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.mtbio.2026.103715_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122856","article-title":"Recent progress in cancer vaccines and nanovaccines","volume":"314","author":"Poudel","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103715_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-024-01628-4","article-title":"Personalized nanovaccines for treating solid cancer metastases","volume":"17","author":"Feng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mtbio.2026.103715_bib24","doi-asserted-by":"crossref","DOI":"10.37349\/ei.2025.1003190","article-title":"Neoantigen vaccines: advancing personalized cancer immunotherapy","volume":"5","author":"Aljabali","year":"2025","journal-title":"Exploration of Immunology"},{"key":"10.1016\/j.mtbio.2026.103715_bib25","article-title":"Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation","volume":"34","author":"Wusiman","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.mtbio.2026.103715_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mattod.2023.06.001","article-title":"Nanoengineered coordination polymers boost cancer immunotherapy","volume":"67","author":"Li","year":"2023","journal-title":"Mater. Today"},{"key":"10.1016\/j.mtbio.2026.103715_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.mattod.2024.07.004","article-title":"Targeting activation of cGAS-STING signaling pathway by engineered biomaterials for enhancing cancer immunotherapy","volume":"78","author":"Liang","year":"2024","journal-title":"Mater. Today"},{"key":"10.1016\/j.mtbio.2026.103715_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202510229","article-title":"A programmable nanovaccine platform based on M13 bacteriophage for personalized cancer vaccine and therapy","volume":"37","author":"Huang","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103715_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122147","article-title":"A programmable oral bacterial hydrogel for controllable production and release of nanovaccine for tumor immunotherapy","volume":"299","author":"Zhang","year":"2023","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.mtbio.2026.103715_bib33","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"34","key":"10.1016\/j.mtbio.2026.103715_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207841119","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103715_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.128061","article-title":"Distinct innate immune activation profiles of an mRNA-lipid nanoparticle vaccine compared to the empty lipid nanoparticle","volume":"71","author":"Zelkoski","year":"2026","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103715_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib50","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1080\/10717544.2022.2086941","article-title":"Phenylboronic ester-modified polymeric nanoparticles for promoting TRP2 peptide antigen delivery in cancer immunotherapy","volume":"29","author":"Wang","year":"2022","journal-title":"Drug Deliv."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103715_bib51","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/acs.accounts.0c00313","article-title":"Nanoscale metal-organic frameworks for cancer immunotherapy","volume":"53","author":"Ni","year":"2020","journal-title":"Acc. Chem. Res."},{"issue":"5","key":"10.1016\/j.mtbio.2026.103715_bib54","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1021\/acs.nanolett.2c04970","article-title":"Orchestrated cytosolic delivery of Antigen and adjuvant by manganese ion-coordinated nanovaccine for enhanced cancer immunotherapy","volume":"23","author":"Gao","year":"2023","journal-title":"Nano Lett."},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib48","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1535-7163.MCT-18-0764","article-title":"A tumor-peptide-based nanoparticle vaccine elicits efficient tumor growth control in Antitumor immunotherapy","volume":"18","author":"He\u00dfe","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"issue":"18","key":"10.1016\/j.mtbio.2026.103715_bib52","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1039\/D1TB02650J","article-title":"MnO2 nanoparticles as a minimalist multimode vaccine adjuvant\/delivery system to regulate antigen presenting cells for tumor immunotherapy","volume":"10","author":"Song","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.mtbio.2026.103715_bib61","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v4.26316","article-title":"Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting","volume":"4","author":"Wiklander","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.mtbio.2026.103715_bib62","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v4.30087","article-title":"Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper","volume":"4","author":"Lener","year":"2015","journal-title":"J. Extracell. Vesicles"},{"issue":"6085","key":"10.1016\/j.mtbio.2026.103715_bib65","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.1219364","article-title":"Computational design of self-assembling protein nanomaterials with atomic level accuracy","volume":"336","author":"King","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103715_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120726","article-title":"P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy","volume":"271","author":"Li","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103715_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/science.adx6291","article-title":"DNA origami vaccines program antigen-focused germinal centers","volume":"391","author":"Romanov","year":"2026","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.mtbio.2026.103715_bib74","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni.3558","article-title":"Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing","volume":"17","author":"Chen","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.mtbio.2026.103715_bib75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s43586-020-00009-8","article-title":"DNA origami","volume":"1","author":"Dey","year":"2021","journal-title":"Nat. Rev. Methods Primers"},{"key":"10.1016\/j.mtbio.2026.103715_bib76","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41587-019-0390-x","article-title":"Peptide-TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens","volume":"38","author":"Lynn","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.mtbio.2026.103715_bib30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","article-title":"Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects","volume":"20","author":"Kon","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"51","key":"10.1016\/j.mtbio.2026.103715_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303261","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103715_bib32","article-title":"mRNA delivery systems for cancer immunotherapy: lipid nanoparticles and beyond","volume":"206","author":"Estap\u00e9","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103715_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12248-025-01051-8","article-title":"Lipid nanoparticles for mRNA delivery in cancer immunotherapy","volume":"27","author":"Alshehry","year":"2025","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103715_bib35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12032-025-02939-3","article-title":"Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy","volume":"42","author":"Abaza","year":"2025","journal-title":"Med. Oncol."},{"issue":"17","key":"10.1016\/j.mtbio.2026.103715_bib36","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.3390\/molecules27175607","article-title":"Lipid nanoparticles for mRNA delivery to enhance cancer immunotherapy","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.mtbio.2026.103715_bib37","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/pharmaceutics14081572","article-title":"mRNA-Loaded lipid nanoparticles targeting dendritic cells for cancer immunotherapy","volume":"14","author":"Sasaki","year":"2022","journal-title":"Pharmaceutics"},{"issue":"23","key":"10.1016\/j.mtbio.2026.103715_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202311574","article-title":"Supramolecular lipid nanoparticles based on host-guest recognition: a new generation delivery System of mRNA vaccines for cancer immunotherapy","volume":"36","author":"Qi","year":"2024","journal-title":"Adv. Mater."},{"issue":"43","key":"10.1016\/j.mtbio.2026.103715_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adx5970","article-title":"Ionizable guanidine-based lipid nanoparticle for targeted mRNA delivery and cancer immunotherapy","volume":"11","author":"Zhang","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.mtbio.2026.103715_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122279","article-title":"Branched hydrophobic tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy","volume":"301","author":"Yan","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103715_bib42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.addr.2020.06.003","article-title":"Dawn of lipid nanoparticles in lymph node targeting: potential in cancer immunotherapy","volume":"167","author":"Nakamura","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103715_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"19","key":"10.1016\/j.mtbio.2026.103715_bib45","doi-asserted-by":"crossref","first-page":"11109","DOI":"10.1021\/acs.chemrev.5b00109","article-title":"Synthetic nanoparticles for vaccines and immunotherapy","volume":"115","author":"Irvine","year":"2015","journal-title":"Chem. Rev."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103715_bib47","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"16","key":"10.1016\/j.mtbio.2026.103715_bib49","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.scib.2022.07.018","article-title":"Antigen self-presenting nanovaccine for cancer immunotherapy","volume":"67","author":"Liang","year":"2022","journal-title":"Science Bulletin"},{"key":"10.1016\/j.mtbio.2026.103715_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122788","article-title":"A carrier-free nanovaccine combined with cancer immunotherapy overcomes gemcitabine resistance","volume":"313","author":"Pan","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103715_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121089","article-title":"Nanovaccine biomineralization for cancer immunotherapy: a NADPH oxidase-inspired strategy for improving antigen cross-presentation via lipid peroxidation","volume":"277","author":"Su","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib56","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s40824-023-00447-x","article-title":"Metal-organic framework-based photodynamic combined immunotherapy against the distant development of triple-negative breast cancer","volume":"27","author":"Liang","year":"2023","journal-title":"Biomater. Res."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201900996","article-title":"Photodynamic therapy combined with antihypoxic signaling and CpG adjuvant as an In Situ tumor vaccine based on metal-organic framework nanoparticles to boost cancer immunotherapy","volume":"9","author":"Cai","year":"2020","journal-title":"Adv. Healthcare Mater."},{"issue":"18","key":"10.1016\/j.mtbio.2026.103715_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202306338","article-title":"Metal-Organic framework-mediated synergistic hypoxia-activated chemo-immunotherapy induced by high intensity focused ultrasound for enhanced cancer theranostics","volume":"20","author":"Sun","year":"2024","journal-title":"Small"},{"issue":"5","key":"10.1016\/j.mtbio.2026.103715_bib59","article-title":"PD-L1 aptamer-functionalized metal-organic framework nanoparticles for robust photo-immunotherapy against cancer with enhanced safety","volume":"62","author":"Zhang","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103715_bib60","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","article-title":"The role of extracellular vesicles in cancer","volume":"186","author":"Kalluri","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.mtbio.2026.103715_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.vesic.2024.100059","article-title":"Prospects and challenges of targeted extracellular vesicles drug delivery for cancer treatment","volume":"4","author":"Maher","year":"2024","journal-title":"Extracellular Vesicle"},{"key":"10.1016\/j.mtbio.2026.103715_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.vesic.2024.100053","article-title":"Extracellular vesicle-based drug delivery systems in cancer","volume":"4","author":"Huang","year":"2024","journal-title":"Extracellular Vesicle"},{"issue":"6297","key":"10.1016\/j.mtbio.2026.103715_bib66","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1126\/science.aaf8818","article-title":"Accurate design of megadalton-scale two-component icosahedral protein complexes","volume":"353","author":"Bale","year":"2016","journal-title":"Science"},{"issue":"7503","key":"10.1016\/j.mtbio.2026.103715_bib67","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature13404","article-title":"Accurate design of co-assembling multi-component protein nanomaterials","volume":"510","author":"King","year":"2014","journal-title":"Nature"},{"issue":"7610","key":"10.1016\/j.mtbio.2026.103715_bib68","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nature18010","article-title":"Design of a hyperstable 60-subunit protein icosahedron","volume":"535","author":"Hsia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103715_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122666","article-title":"Self-assembled protein vesicles as vaccine delivery platform to enhance antigen-specific immune responses","volume":"311","author":"Li","year":"2024","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib71","doi-asserted-by":"crossref","first-page":"10722","DOI":"10.1021\/acsnano.1c04078","article-title":"Antigen-Presenting, self-assembled protein nanobarrels as an adjuvant-free vaccine platform against influenza virus","volume":"15","author":"Kang","year":"2021","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.mtbio.2026.103715_bib72","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.3390\/cancers13122909","article-title":"Development of a virus-like particle-based Anti-HER2 breast cancer vaccine","volume":"13","author":"Hu","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.mtbio.2026.103715_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2019.03.037","article-title":"Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy","volume":"207","author":"Xu","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103715_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119649","article-title":"Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses","volume":"230","author":"Liu","year":"2020","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.mtbio.2026.103715_bib79","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"issue":"39","key":"10.1016\/j.mtbio.2026.103715_bib80","doi-asserted-by":"crossref","first-page":"27077","DOI":"10.1021\/acsnano.4c11652","article-title":"Blood distribution of SARS-CoV-2 lipid nanoparticle mRNA vaccine in humans","volume":"18","author":"Kent","year":"2024","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103715_bib81","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcyt.2021.08.005","article-title":"Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials","volume":"24","author":"Ingels","year":"2022","journal-title":"Cytotherapy"},{"issue":"13","key":"10.1016\/j.mtbio.2026.103715_bib82","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1021\/acs.nanolett.1c01353","article-title":"Scalable mRNA and siRNA lipid nanoparticle production using a parallelized microfluidic device","volume":"21","author":"Shepherd","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.103715_bib84","year":"2026"},{"issue":"26","key":"10.1016\/j.mtbio.2026.103715_bib85","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1200\/JCO-26-00835","article-title":"Intismeran autogene plus pembrolizumab versus pembrolizumab alone in high-risk resected Melanoma: 5-Year update of the randomized phase IIb KEYNOTE-942 study","volume":"44","author":"Khattak","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103715_bib86","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","article-title":"Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy","volume":"14","author":"Shae","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103715_bib87","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cell.2019.02.029","article-title":"Reassessment of exosome composition","volume":"177","author":"Jeppesen","year":"2019","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103715_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103715_bib89","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1071008","article-title":"Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC","volume":"5","author":"Besse","year":"2016","journal-title":"OncoImmunology"},{"issue":"697","key":"10.1016\/j.mtbio.2026.103715_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf3309","article-title":"A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses","volume":"15","author":"Cohen","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103715_bib91","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1002\/bit.24907","article-title":"Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine","volume":"110","author":"Chuan","year":"2013","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.mtbio.2026.103715_bib92","article-title":"Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens","volume":"3","author":"Kraft","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.mtbio.2026.103715_bib93","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.4049\/jimmunol.135.4.2319","article-title":"Carrier-induced epitopic suppression, a major issue for future synthetic vaccines","volume":"135","author":"Schutze","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.mtbio.2026.103715_bib94","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1016\/j.vaccine.2010.02.103","article-title":"Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies","volume":"28","author":"Jegerlehner","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.mtbio.2026.103715_bib95","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41541-022-00547-0","article-title":"CD4 T cell epitope abundance in ferritin core potentiates responses to hemagglutinin nanoparticle vaccines","volume":"7","author":"Nelson","year":"2022","journal-title":"npj Vaccines"},{"issue":"Pt B","key":"10.1016\/j.mtbio.2026.103715_bib96","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of virus-like particles for vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"N. Biotech."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103715_bib97","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/lam.12695","article-title":"Yeast as an expression system for producing virus-like particles: what factors do we need to consider?","volume":"64","author":"Kim","year":"2017","journal-title":"Lett. Appl. Microbiol."},{"key":"10.1016\/j.mtbio.2026.103715_bib98","first-page":"516","article-title":"Cancer vaccine designed from homologous ferritin-based fusion protein with enhanced DC-T cell crosstalk for durable adaptive immunity against tumors","volume":"46","author":"Wu","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.mtbio.2026.103715_bib99","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/s12951-024-02837-2","article-title":"Recombinant ferritin-based nanoparticles as neoantigen carriers significantly inhibit tumor growth and metastasis","volume":"22","author":"Zheng","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"825","key":"10.1016\/j.mtbio.2026.103715_bib100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adr1777","article-title":"A modular metalloprotein in situ vaccine for cancer immunotherapy in mouse models of breast cancer","volume":"17","author":"Liu","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103715_bib101","article-title":"Neoantigen-displaying protein nanoparticles as a therapeutic cancer vaccine against melanoma","volume":"14","author":"Kim","year":"2025","journal-title":"Adv. Healthcare Mater."},{"issue":"5","key":"10.1016\/j.mtbio.2026.103715_bib103","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.mtbio.2026.103715_bib105","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103715_bib107","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.mtbio.2026.103715_bib108","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.mtbio.2026.103715_bib109","series-title":"Elicio Therapeutics, Inc. Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer","year":"2026"},{"key":"10.1016\/j.mtbio.2026.103715_bib110","series-title":"Biontech Provides Update on Phase 2 Clinical Trial of Autogene Cevumeran in Resected Colorectal Cancer","author":"BioNTech","year":"2026"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib111","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/iub.1621","article-title":"Ferritin, cellular iron storage and regulation","volume":"69","author":"Arosio","year":"2017","journal-title":"IUBMB Life"},{"issue":"8","key":"10.1016\/j.mtbio.2026.103715_bib112","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1073\/pnas.0913192107","article-title":"Binding and uptake of H-ferritin are mediated by human transferrin receptor-1","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib113","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.mtbio.2026.103715_bib114","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3389\/fimmu.2018.01643","article-title":"Current concepts of antigen cross-presentation","volume":"9","author":"Embgenbroich","year":"2018","journal-title":"Front. Immunol."},{"issue":"22","key":"10.1016\/j.mtbio.2026.103715_bib115","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.vaccine.2021.04.021","article-title":"Efficient immunogenic peptide antigen delivery to dendritic cells using an ESCRT-mediated extracellular vesicle formation method","volume":"39","author":"Kimura","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.mtbio.2026.103715_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119518","article-title":"Development of DNA-anchored assembly of small extracellular vesicle for efficient antigen delivery to antigen presenting cells","volume":"225","author":"Matsumoto","year":"2019","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103715_bib117","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/cancers11020138","article-title":"Anti-Cancer vaccine for HPV-associated neoplasms: focus on a therapeutic HPV vaccine based on a novel tumor antigen delivery method using endogenously engineered exosomes","volume":"11","author":"Di Bonito","year":"2019","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.mtbio.2026.103715_bib118","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12247","article-title":"Generalized Modules for Membrane Antigens (GMMA), an outer membrane vesicle-based vaccine platform, for efficient viral antigen delivery","volume":"11","author":"Hu","year":"2022","journal-title":"J. Extracell. Vesicles"},{"issue":"12","key":"10.1016\/j.mtbio.2026.103715_bib217","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1021\/acs.biomac.2c00993","article-title":"Mannosylated polycations target CD206+ antigen-presenting cells and mediate T-cell-specific activation in cancer vaccination","volume":"23","author":"Bellato","year":"2022","journal-title":"Biomacromolecules"},{"issue":"7693","key":"10.1016\/j.mtbio.2026.103715_bib119","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.mtbio.2026.103715_bib120","doi-asserted-by":"crossref","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mtbio.2026.103715_bib121","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"7823","key":"10.1016\/j.mtbio.2026.103715_bib122","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib123","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013130","article-title":"Opportunity knocking: shared tumor-associated antigen vaccines against global cancer pandemic","volume":"14","author":"Finn","year":"2026","journal-title":"J. ImmunoTher. Cancer"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib222","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/s12276-024-01259-2","article-title":"The identification of effective tumor-suppressing neoantigens using a tumor-reactive TIL TCR-pMHC ternary complex","volume":"56","author":"Kim","year":"2024","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103715_bib124","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.mtbio.2026.103715_bib125","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202305832","article-title":"In situ Hydrogel modulates cDC1-Based antigen presentation and cancer stemness to enhance cancer vaccine efficiency","volume":"11","author":"Gao","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.mtbio.2026.103715_bib126","article-title":"Nanoadjuvant-integrated organic biomaterials for immune engineering: mechanisms, design strategies, and translational applications","volume":"38","author":"Tang","year":"2026","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.mtbio.2026.103715_bib127","article-title":"Biomaterial-based strategies for postoperative residual tumors: from margin clearance to immune control and tissue repair","volume":"38","author":"Zou","year":"2026","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.mtbio.2026.103715_bib128","article-title":"Nanomaterials reshaping cancer radiotherapy: radiosensitization mechanisms, delivery and theranostic platforms, multimodal synergy, and clinical translation strategies","volume":"38","author":"Liu","year":"2026","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.mtbio.2026.103715_bib129","article-title":"Nanoscale delivery systems for hepatocellular carcinoma: functionalization, delivery strategies, and clinical challenges","volume":"38","author":"Fu","year":"2026","journal-title":"Mater. Today Bio"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103715_bib218","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2017.52","article-title":"A STING-activating nanovaccine for cancer immunotherapy","volume":"12","author":"Luo","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103715_bib139","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat. Commun."},{"issue":"7456","key":"10.1016\/j.mtbio.2026.103715_bib130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103715_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113892","article-title":"Ferritin nanocage: a promising and designable multi-module platform for constructing dynamic nanoassembly-based drug nanocarrier","volume":"176","author":"Zhang","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2026.103715_bib132","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.phrs.2016.03.002","article-title":"Ferritin nanocages: a biological platform for drug delivery, imaging and theranostics in cancer","volume":"107","author":"Truffi","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"41","key":"10.1016\/j.mtbio.2026.103715_bib133","doi-asserted-by":"crossref","first-page":"14900","DOI":"10.1073\/pnas.1407808111","article-title":"H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection","volume":"111","author":"Liang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mtbio.2026.103715_bib134","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jconrel.2019.09.002","article-title":"Ferritin drug carrier (FDC) for tumor targeting therapy","volume":"311\u2013312","author":"He","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103715_bib135","article-title":"Toward understanding the kinetics of disassembly of ferritins of varying origin and subunit composition","volume":"28","author":"Krausova","year":"2022","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.mtbio.2026.103715_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123488","article-title":"Multi-bioactive poly(amino acid)-metal-organic framework nanocomposite for reinforced cascading photodynamic immunotherapy of cancer","volume":"324","author":"Sun","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103715_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121261","article-title":"Immune-regulating bimetallic metal-organic framework nanoparticles designed for cancer immunotherapy","volume":"280","author":"Dai","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103715_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.celbio.2026.100373","article-title":"Ferritin-based photoimmunotherapeutic Trojan horse in situ vaccine for glioblastoma and brain metastases via meningeal lymphatic delivery","volume":"2","author":"Zhang","year":"2026","journal-title":"Cell Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103715_bib140","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41467-023-37547-0","article-title":"Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues","volume":"14","author":"Abelin","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103715_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1690101","article-title":"MAPPs assays for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform","volume":"16","author":"Karle","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103715_bib142","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","article-title":"Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo","volume":"53","author":"Kato","year":"2020","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.mtbio.2026.103715_bib143","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/s41590-023-01597-9","article-title":"Molecular basis for potent B cell responses to antigen displayed on particles of viral size","volume":"24","author":"Brooks","year":"2023","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.mtbio.2026.103715_bib144","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"5138","key":"10.1016\/j.mtbio.2026.103715_bib145","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1126\/science.8248784","article-title":"The influence of antigen organization on B cell responsiveness","volume":"262","author":"Bachmann","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103715_bib146","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr. Opin. Virol."},{"issue":"25\u201326","key":"10.1016\/j.mtbio.2026.103715_bib147","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1016\/S0264-410X(02)00266-9","article-title":"A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses","volume":"20","author":"Jegerlehner","year":"2002","journal-title":"Vaccine"},{"issue":"5947","key":"10.1016\/j.mtbio.2026.103715_bib148","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/307178a0","article-title":"Human hepatitis B vaccine from recombinant yeast","volume":"307","author":"McAleer","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103715_bib149","article-title":"Engineered human ferritin nanoparticles for direct delivery of tumor antigens to lymph node and cancer immunotherapy","volume":"6","author":"Lee","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mtbio.2026.103715_bib150","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57659","article-title":"Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens","volume":"9","author":"Ueda","year":"2020","journal-title":"eLife"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib151","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"issue":"6492","key":"10.1016\/j.mtbio.2026.103715_bib152","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay5051","article-title":"De novo protein design enables the precise induction of RSV-neutralizing antibodies","volume":"368","author":"Sesterhenn","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.mtbio.2026.103715_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008665","article-title":"Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens","volume":"16","author":"Antanasijevic","year":"2020","journal-title":"PLoS Pathog."},{"issue":"12","key":"10.1016\/j.mtbio.2026.103715_bib154","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202310910","article-title":"Empowering site-specific bioconjugations in vitro and in vivo: advances in sortase engineering and sortase-mediated ligation","volume":"63","author":"Zou","year":"2024","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.mtbio.2026.103715_bib155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nano.2018.11.009","article-title":"Ferritin nanoparticle-based SpyTag\/SpyCatcher-enabled click vaccine for tumor immunotherapy","volume":"16","author":"Wang","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.mtbio.2026.103715_bib156","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.1038\/s41467-024-52908-z","article-title":"Self-assembling nanoparticle engineered from the ferritinophagy complex as a rabies virus vaccine candidate","volume":"15","author":"Fu","year":"2024","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103715_bib157","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat. Med."},{"issue":"6309","key":"10.1016\/j.mtbio.2026.103715_bib158","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/349541a0","article-title":"Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts","volume":"349","author":"Lawson","year":"1991","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103715_bib159","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0005-2728(96)00022-9","article-title":"The ferritins: molecular properties, iron storage function and cellular regulation","volume":"1275","author":"Harrison","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.mtbio.2026.103715_bib160","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bbagen.2010.03.019","article-title":"X-ray structures of ferritins and related proteins","volume":"1800","author":"Crichton","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mtbio.2026.103715_bib161","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202000208","article-title":"Human ferritin platform and its optimized structures to enhance anti-cancer immunity","volume":"4","author":"Lee","year":"2021","journal-title":"Adv. Therapeut."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103715_bib162","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00792-005-0484-x","article-title":"A highly thermostable ferritin from the hyperthermophilic archaeal anaerobe Pyrococcus furiosus","volume":"10","author":"Tatur","year":"2006","journal-title":"Extremophiles"},{"key":"10.1016\/j.mtbio.2026.103715_bib163","article-title":"Engineering neoantigens to form immunogenic biopolymer particles targeting metastatic breast cancer","volume":"38","author":"Pounraj","year":"2024","journal-title":"Appl. Mater. Today"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib164","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.2016","article-title":"Challenges in exploiting human H ferritin nanoparticles for drug delivery: navigating physiological constraints","volume":"16","author":"Macone","year":"2024","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"issue":"8121","key":"10.1016\/j.mtbio.2026.103715_bib165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41586-026-10464-0","article-title":"De novo design of quasisymmetric two-component protein cages","volume":"655","author":"Wang","year":"2026","journal-title":"Nature"},{"issue":"8121","key":"10.1016\/j.mtbio.2026.103715_bib166","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-026-10554-z","article-title":"Design of one-component quasisymmetric protein nanocages","volume":"655","author":"Lee","year":"2026","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.mtbio.2026.103715_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113552","article-title":"Antigen spacing on protein nanoparticles influences antibody responses to vaccination","volume":"42","author":"Ellis","year":"2023","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib220","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib221","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41592-023-02087-4","article-title":"AlphaFold predictions are valuable hypotheses and accelerate but do not replace experimental structure determination","volume":"21","author":"Terwilliger","year":"2024","journal-title":"Nat. Methods"},{"issue":"1\u20132","key":"10.1016\/j.mtbio.2026.103715_bib167","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib168","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103715_bib169","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2026.103715_bib170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606569","article-title":"Broad neutralization responses against oncogenic human papillomaviruses induced by a minor capsid L2 polytope genetically incorporated into bacterial ferritin nanoparticles","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib171","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.00866-09","article-title":"Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization","volume":"84","author":"Cheng","year":"2010","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103715_bib172","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00262-013-1400-3","article-title":"Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients","volume":"62","author":"Morse","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib173","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.mtbio.2026.103715_bib174","doi-asserted-by":"crossref","DOI":"10.1093\/protein\/gzaf003","article-title":"Tuning ProteinMPNN to reduce protein visibility via MHC Class I through direct preference optimization","volume":"38","author":"Gasser","year":"2025","journal-title":"Protein Eng. Des. Sel."},{"issue":"W1","key":"10.1016\/j.mtbio.2026.103715_bib175","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103715_bib176","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.mtbio.2026.103715_bib177","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3389\/fimmu.2020.00698","article-title":"Applying MAPPs assays to assess drug immunogenicity","volume":"11","author":"Karle","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103715_bib178","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/antib14030062","article-title":"Immunogenicity risk assessment of biotherapeutics using an Ex vivo B cell assay","volume":"14","author":"Budge","year":"2025","journal-title":"Antibodies"},{"issue":"5","key":"10.1016\/j.mtbio.2026.103715_bib179","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1208\/s12248-020-00491-8","article-title":"Fit-for-Purpose validation and establishment of assay acceptance and reporting criteria of dendritic cell activation assay contributing to the assessment of immunogenicity risk","volume":"22","author":"Wickramarachchi","year":"2020","journal-title":"AAPS J."},{"issue":"12","key":"10.1016\/j.mtbio.2026.103715_bib180","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.tips.2023.10.002","article-title":"Emerging approaches to induce immune tolerance to therapeutic proteins","volume":"44","author":"Noel","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"17","key":"10.1016\/j.mtbio.2026.103715_bib181","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.4155\/bio-2018-0246","article-title":"Nonclinical immunogenicity risk assessment of therapeutic proteins","volume":"11","author":"Tourdot","year":"2019","journal-title":"Bioanalysis"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103715_bib182","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1208\/s12248-020-00447-y","article-title":"Clinical immunogenicity risk assessment for a fusion protein","volume":"22","author":"Sperinde","year":"2020","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib183","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302095","article-title":"Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics","volume":"7","author":"Di Ianni","year":"2024","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.mtbio.2026.103715_bib184","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1295285","article-title":"Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS\/MS to support immunogenicity risk assessment in drug development","volume":"14","author":"Lee","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103715_bib185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1723110","article-title":"T cell assays for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform","volume":"16","author":"Tourdot","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103715_bib186","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1704045","article-title":"Dendritic cell maturation assay for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform","volume":"16","author":"Ackaert","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib187","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13036-026-00685-2","article-title":"Host cell protein impurities in therapeutic proteins: overview of advances in detection, nonconventional removal technologies and immunogenicity assessment","volume":"20","author":"Alhuthali","year":"2026","journal-title":"J. Biol. Eng."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib189","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-022-00447-3","article-title":"Pandemic-response adenoviral vector and RNA vaccine manufacturing","volume":"7","author":"Kis","year":"2022","journal-title":"npj Vaccines"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib190","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.trecan.2026.02.003","article-title":"From prediction to precision: how immunopeptidomics advances neoantigen discovery","volume":"12","author":"Shapiro","year":"2026","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib191","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41596-019-0133-y","article-title":"Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics","volume":"14","author":"Purcell","year":"2019","journal-title":"Nat. Protoc."},{"issue":"7681","key":"10.1016\/j.mtbio.2026.103715_bib192","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"Luksza","year":"2017","journal-title":"Nature"},{"issue":"6280","key":"10.1016\/j.mtbio.2026.103715_bib193","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"7549","key":"10.1016\/j.mtbio.2026.103715_bib194","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103715_bib195","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103715_bib196","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","article-title":"De novo design of protein structure and function with RFdiffusion","volume":"620","author":"Watson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103715_bib197","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.add2187","article-title":"Robust deep learning-based protein sequence design using ProteinMPNN","volume":"378","author":"Dauparas","year":"2022","journal-title":"Science"},{"issue":"6693","key":"10.1016\/j.mtbio.2026.103715_bib198","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl2528","article-title":"Generalized biomolecular modeling and design with RoseTTAFold All-Atom","volume":"384","author":"Krishna","year":"2024","journal-title":"Science"},{"issue":"8016","key":"10.1016\/j.mtbio.2026.103715_bib199","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib200","article-title":"Bayesian optimization and machine learning for vaccine formulation development","volume":"20","author":"Li","year":"2025","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103715_bib201","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1011247","article-title":"Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine","volume":"20","author":"Valega-Mackenzie","year":"2024","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.mtbio.2026.103715_bib202","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s43856-023-00425-3","article-title":"Harnessing artificial intelligence to improve clinical trial design","volume":"3","author":"Zhang","year":"2023","journal-title":"Commun. Med."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103715_bib203","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cels.2019.05.004","article-title":"Quantification of uncertainty in Peptide-MHC binding prediction improves high-affinity peptide selection for therapeutic design","volume":"9","author":"Zeng","year":"2019","journal-title":"Cell Syst."},{"issue":"6","key":"10.1016\/j.mtbio.2026.103715_bib204","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/acs.jproteome.9b00874","article-title":"Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data","volume":"19","author":"Reynisson","year":"2020","journal-title":"J. Proteome Res."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib205","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","article-title":"MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing","volume":"11","author":"O'Donnell","year":"2020","journal-title":"Cell Syst."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib206","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqag008","article-title":"Enhancing protein immunogenicity prediction via uncertainty weighted deep ensemble","volume":"7","author":"Qayyum","year":"2026","journal-title":"Oxford Open Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib207","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqag003","article-title":"ImmUQBench: a benchmark on uncertainty quantification of protein immunogenicity prediction","volume":"7","author":"Qayyum","year":"2026","journal-title":"Oxford Open Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib208","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12248-024-01003-8","article-title":"Evaluating the immunogenicity risk of protein therapeutics by augmenting T cell epitope prediction with clinical factors","volume":"27","author":"Hu","year":"2025","journal-title":"AAPS J."},{"key":"10.1016\/j.mtbio.2026.103715_bib209","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.csbj.2020.12.024","article-title":"Deimmunization of protein therapeutics - recent advances in experimental and computational epitope prediction and deletion","volume":"19","author":"Zinsli","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.mtbio.2026.103715_bib210","article-title":"A highly effective System for predicting MHC-II epitopes with immunogenicity","volume":"12","author":"Xu","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103715_bib211","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/acs.nanolett.8b00432","article-title":"A direct comparison of in vitro and in vivo nucleic acid delivery mediated by hundreds of nanoparticles reveals a weak correlation","volume":"18","author":"Paunovska","year":"2018","journal-title":"Nano Lett."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103715_bib212","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41565-021-01030-y","article-title":"Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles","volume":"17","author":"Hatit","year":"2022","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103715_bib213","doi-asserted-by":"crossref","first-page":"142","DOI":"10.34133\/csbj.0142","article-title":"Adversarial sequence mutations in AlphaFold and ESMFold reveal nonphysical structural invariance, confidence failures, and concerns for protein design","volume":"35","author":"Feldman","year":"2026","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103715_bib214","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41565-025-01975-4","article-title":"Designing lipid nanoparticles using a transformer-based neural network","volume":"20","author":"Chan","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"7","key":"10.1016\/j.mtbio.2026.103715_bib215","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.mtbio.2026.103715_bib216","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426009609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426009609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:49:54Z","timestamp":1793450994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006426009609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":217,"alternative-id":["S2590006426009609"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103715","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bottleneck-first evaluation of antigen delivery platforms for therapeutic cancer vaccines","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103715"}}